{"source": "The New York Times", "lead_paragraph": "By agreeing to sell his company Abraxis BioScience, Patrick Soon-Shiong is adding to a fortune that Forbes values at $4 billion.", "keywords": [{"rank": "1", "value": "Abraxis BioScience, Incorporated", "is_major": "N", "name": "organizations"}, {"rank": "2", "value": "Celgene Corporation", "is_major": "N", "name": "organizations"}, {"rank": "3", "value": "Mergers, Acquisitions and Divestitures", "is_major": "N", "name": "subject"}, {"rank": "4", "value": "Drugs (Pharmaceuticals)", "is_major": "N", "name": "subject"}], "multimedia": [], "snippet": "By agreeing to sell his company Abraxis BioScience, Patrick Soon-Shiong is adding to a fortune that Forbes values at $4 billion.", "print_page": "3", "blog": [], "headline": {"main": "Prominent Drug Chief to Sell Abraxis BioScience to Celgene for $2.9 Billion", "seo": "Celgene to Buy Abraxis BioScience for $2.9 Billion", "print_headline": "Prominent Drug Chief to Sell Abraxis BioScience to Celgene for $2.9 Billion"}, "_id": "54180f3438f0d851fd3a8dad", "web_url": "http://www.nytimes.com/2010/07/01/health/01drug.html", "slideshow_credits": null, "byline": {"person": [{"organization": "", "rank": 1, "role": "reported", "lastname": "POLLACK", "firstname": "Andrew"}], "original": "By ANDREW POLLACK", "contributor": ""}, "news_desk": "Business", "word_count": "829", "document_type": "article", "type_of_material": "News", "abstract": null, "pub_date": "2010-07-01T00:00:00Z", "subsection_name": null, "section_name": "Health"}